CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-κB and NF-κB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells

Journal of Experimental Therapeutics and Oncology

Volumn 7, Issue 1, 2008, Pages 31-39

  Deeb, Dorrah ^a   Gao, Xiaohua ^a   Dulchavsky, Scott A ^a   Gautam, Subhash C ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Akt; CDDOs; NF B; Prostate; TRAMP

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID IMIDAZOLE DERIVATIVE; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID METHYL ESTER; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROCASPASE 3; PROCASPASE 8; PROCASPASE 9; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; MALE; MICE; NF-KAPPA B; NITRIC OXIDE; OLEANOLIC ACID; PROSTATIC NEOPLASMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 42049099974     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Garnick, M.B. Hormonal therapy in the management of prostate cancer: From Higgins to the present. Urology 49:5-15, 1997.
2. Hanks, GE. Long-term control of prostate cancer with radiation. Urol Clin North Amer 23:605-616, 1996.
3. Crawford ED, Rosenblum M, Ziada AM, and Lange PH. Overview: Hormone refractory prostate cancer. Urology 54:1-7, 1999.
4. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case control study. Oncol Rep 7:169-170, 2000.
5. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64:3334-3343, 2004.
6. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 10:7727-7737, 2004.
7. Fries J. Toward understanding of NSAID-related adverse events; the contribution of longitudinal data. Scand Rheumatol 102 (Suppl):3-8, 1996.
8. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Eng J Med 353:1071-1080, 2005.
9. Surh Y-J. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutation Res 428: 305, 1999.
10. Sugihara N, Arakawa T, Ohnishi M, and Furuno K. Anti- and pro-oxidative effects of flavonoids on metal-induced lipid hydoperoxide-dependent lipid peroxidation in cultured hepatocytes loaded with a-linolenic acid. Free Radic Biol Med 27: 1313, 1999.
11. Dugas AJ, Castaneda-Acosta J, Bonin GC, Price KL, Fischer NH. Evaluation of the total peroxy radical-scavenging capacity of flanonoids: structure-activity relationships. J Nat Prod 63: 327, 2000.
12. Huang MT, Ho CT, Wang ZY, Ferraro T, Lou YR, Stauber K, et al. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res 54:701-708, 1994.
13. Nishino H, Nishino A, Takayasu J, Hasegawa T, Iwashima A, Hirabayashi K, et al. Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13- accetate by some oleanane-type triterpenoid compounds. Cancer Res 48:5210-5215, 1988.
14. Ryu SY, Oak MH, Yoon SK, Cho DI, Yoo GS, Kim TS, et al. Anti-allergic and anti-inflammatory triterpenes from the herb of Prunella vulgaris. Planta Med 66:358-360, 2000.
15. Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, Sporn MB. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Biorg Med Chem Lett 8:2711-2114, 1998.
16. Honda T, Rounds BV, Bore L, Favaloro FG, Gibble GW, Suh N, et al. Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Chem Lett 9:3429-3434, 1999.
17. Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky S, Gautam S. Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-□B and Notch1 signaling. J Neurooncol 2007 Mar 15; [Epub ahead of print].
18. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood. 99:326-35, 2002.
19. Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB. A synthetic triterpenoid, CDDO-Me, inhibits 1kappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 12:1828-1838, 2006.
20. Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 63:5926-5939, 2003.
21. Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res 64:7570-7578, 2004.
22. Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 9:2798-2806, 2003.
23. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 65:4799-4808, 2005.
24. Deeb D, Jiang H, Gao X, Divine G, Dulchavsky SA, Gautam SC. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J Exp Therapeutics and Oncol 2:81-91, 2004.
25. Wang S, Gao J, Lei Q, Rozenguri N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221, 2003.
26. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Sci Acad USA 100:7841-7846, 2003.
27. Kaplan-Lefco PJ, Chen T-M, Ittman MM, Barrios RJ, Ayala GE, Huss WJ, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55:219-237, 2003.
28. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 56:4096, 1996.
29. Ikeda T, Sporn M, Honda T, Gribble GW, Kufe D. The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res 63 (17):5551-8, 2003.
30. Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, et al. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res 63:1371-6, 2003.
31. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013-2026, 1994.
32. Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, et al. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 64:7927-7935, 2004.
33. Ito Y, Pandey P, Sporn MB, Datta R, Kharbanda S, Kufe D. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol 59:1094-1099, 2001.
34. Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M, Ruvolo PP. The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 19:1350-4, 2005.
35. Chintharlapalli S, Papineni S, Konopleva M, Andreef M, Samudio I, Safe S. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol Pharmacol 68:119-28, 2005.
36. Marte BM and Downward J. PKB/Akt: connecting phosphoinositide3-kinase to cell survival and beyond. Trends Biochem Sci 22:355-358, 1997.
37. Altomare DA and Testa JR. Perturbations of the Akt signaling pathway in human cancer. Oncogene 24:7455-7464, 2005.
38. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery Cell 91:231-241, 1997.
39. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Standbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-1321, 1998.
40. Baeurele PA, and Henkel T. Function and activation of NF-kB in the immune system. Annu Rev Immunol 12:141-179, 1994.
41. Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr,and Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61:187-196, 2003.
42. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, and Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24:200-216, 2004.
43. Hidalgo M and Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19:6680-6686, 2000.
44. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncology 16:525-537, 2005.